Ionis Pharmaceuticals Inc. (NASDAQ:IONS) SVP C Frank Bennett sold 5,000 shares of the stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $34.00, for a total value of $170,000.00. Following the completion of the transaction, the senior vice president now owns 15,803 shares in the company, valued at approximately $537,302. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) opened at 40.95 on Friday. Ionis Pharmaceuticals Inc. has a 12-month low of $19.59 and a 12-month high of $63.71. The stock has a 50 day moving average price of $31.56 and a 200-day moving average price of $30.31. The company’s market capitalization is $4.95 billion.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Wednesday, November 9th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by $0.02. Ionis Pharmaceuticals had a negative return on equity of 117.31% and a negative net margin of 77.30%. The firm earned $110.90 million during the quarter, compared to analysts’ expectations of $114.65 million. The business’s quarterly revenue was up 125.9% on a year-over-year basis. Equities analysts predict that Ionis Pharmaceuticals Inc. will post ($1.11) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

A number of institutional investors have recently made changes to their positions in IONS. FMR LLC raised its position in shares of Ionis Pharmaceuticals by 1.8% in the second quarter. FMR LLC now owns 18,117,448 shares of the company’s stock worth $421,955,000 after buying an additional 325,351 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Ionis Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 8,794,783 shares of the company’s stock worth $204,831,000 after buying an additional 349,172 shares during the last quarter. Baillie Gifford & Co. raised its position in shares of Ionis Pharmaceuticals by 4.6% in the second quarter. Baillie Gifford & Co. now owns 8,663,711 shares of the company’s stock worth $201,778,000 after buying an additional 379,973 shares during the last quarter. BB Biotech AG raised its position in shares of Ionis Pharmaceuticals by 0.8% in the third quarter. BB Biotech AG now owns 7,163,172 shares of the company’s stock worth $262,459,000 after buying an additional 58,334 shares during the last quarter. Finally, Waddell & Reed Financial Inc. raised its position in shares of Ionis Pharmaceuticals by 2.6% in the second quarter. Waddell & Reed Financial Inc. now owns 5,949,200 shares of the company’s stock worth $138,557,000 after buying an additional 148,100 shares during the last quarter. Institutional investors own 89.56% of the company’s stock.

Several brokerages have recently commented on IONS. Leerink Swann reissued a “market perform” rating and issued a $36.00 price objective (up from $26.00) on shares of Ionis Pharmaceuticals in a research note on Tuesday, August 2nd. Vetr downgraded Ionis Pharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $37.34 price objective for the company. in a research note on Wednesday. Zacks Investment Research raised Ionis Pharmaceuticals from a “sell” rating to a “hold” rating and set a $41.00 price objective for the company in a research note on Wednesday, August 3rd. Cowen and Company reissued a “buy” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, August 3rd. Finally, Piper Jaffray Cos. reissued a “buy” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $41.78.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.

5 Day Chart for NASDAQ:IONS

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.